These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

438 related items for PubMed ID: 19841190

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Proteasome inhibition by bortezomib decreases proliferation and increases apoptosis in ovarian granulosa cell tumors.
    Chu S, Alexiadis M, Fuller PJ.
    Reprod Sci; 2009 Apr; 16(4):397-407. PubMed ID: 19087975
    [Abstract] [Full Text] [Related]

  • 24. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells.
    Altun M, Galardy PJ, Shringarpure R, Hideshima T, LeBlanc R, Anderson KC, Ploegh HL, Kessler BM.
    Cancer Res; 2005 Sep 01; 65(17):7896-901. PubMed ID: 16140960
    [Abstract] [Full Text] [Related]

  • 25. Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.
    Pekol T, Daniels JS, Labutti J, Parsons I, Nix D, Baronas E, Hsieh F, Gan LS, Miwa G.
    Drug Metab Dispos; 2005 Jun 01; 33(6):771-7. PubMed ID: 15764713
    [Abstract] [Full Text] [Related]

  • 26. The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide.
    O'Connor OA, Smith EA, Toner LE, Teruya-Feldstein J, Frankel S, Rolfe M, Wei X, Liu S, Marcucci G, Chan KK, Chanan-Khan A.
    Clin Cancer Res; 2006 May 01; 12(9):2902-11. PubMed ID: 16675587
    [Abstract] [Full Text] [Related]

  • 27. The role of bortezomib in the treatment of lymphoma.
    Barr P, Fisher R, Friedberg J.
    Cancer Invest; 2007 Dec 01; 25(8):766-75. PubMed ID: 18058474
    [Abstract] [Full Text] [Related]

  • 28. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.
    Boissy P, Andersen TL, Lund T, Kupisiewicz K, Plesner T, Delaissé JM.
    Leuk Res; 2008 Nov 01; 32(11):1661-8. PubMed ID: 18394701
    [Abstract] [Full Text] [Related]

  • 29. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.
    Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, Wiethe C, Winkler TH, Kalden JR, Manz RA, Voll RE.
    Nat Med; 2008 Jul 01; 14(7):748-55. PubMed ID: 18542049
    [Abstract] [Full Text] [Related]

  • 30. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
    Colado E, Alvarez-Fernández S, Maiso P, Martín-Sánchez J, Vidriales MB, Garayoa M, Ocio EM, Montero JC, Pandiella A, San Miguel JF.
    Haematologica; 2008 Jan 01; 93(1):57-66. PubMed ID: 18166786
    [Abstract] [Full Text] [Related]

  • 31. G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation.
    Yang YM, Lee S, Nam CW, Ha JH, Jayaraman M, Dhanasekaran DN, Lee CH, Kwak MK, Kim SG.
    Carcinogenesis; 2010 Jul 01; 31(7):1230-7. PubMed ID: 20478922
    [Abstract] [Full Text] [Related]

  • 32. BCL-2 family regulation by the 20S proteasome inhibitor bortezomib.
    Fennell DA, Chacko A, Mutti L.
    Oncogene; 2008 Feb 21; 27(9):1189-97. PubMed ID: 17828309
    [Abstract] [Full Text] [Related]

  • 33. Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.
    Yerlikaya A, Erin N.
    Int J Mol Med; 2008 Dec 21; 22(6):817-23. PubMed ID: 19020781
    [Abstract] [Full Text] [Related]

  • 34. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Aghajanian C, Blessing JA, Darcy KM, Reid G, DeGeest K, Rubin SC, Mannel RS, Rotmensch J, Schilder RJ, Riordan W, Gynecologic Oncology Group.
    Gynecol Oncol; 2009 Nov 21; 115(2):215-20. PubMed ID: 19712963
    [Abstract] [Full Text] [Related]

  • 35. Molecular and functional dissection of the H-2Db-restricted subdominant cytotoxic T-cell response to lymphocytic choriomeningitis virus.
    Hudrisier D, Riond J, Gairin JE.
    J Virol; 2001 Mar 21; 75(5):2468-71. PubMed ID: 11160751
    [Abstract] [Full Text] [Related]

  • 36. The role of proteasome in malignant diseases.
    Moran E, Nencioni A.
    J BUON; 2007 Sep 21; 12 Suppl 1():S95-9. PubMed ID: 17935285
    [Abstract] [Full Text] [Related]

  • 37. Interleukin-10 plays an early role in generating virus-specific T cell anergy.
    Maris CH, Chappell CP, Jacob J.
    BMC Immunol; 2007 Jun 14; 8():8. PubMed ID: 17570849
    [Abstract] [Full Text] [Related]

  • 38. The persisting challenge of selective and specific proteasome inhibition.
    Groll M, Huber R, Moroder L.
    J Pept Sci; 2009 Feb 14; 15(2):58-66. PubMed ID: 19109822
    [Abstract] [Full Text] [Related]

  • 39. Proteasome inhibition: mechanism of action.
    DeMartino GN.
    J Natl Compr Canc Netw; 2004 Nov 14; 2 Suppl 4():S5-9. PubMed ID: 19791423
    [Abstract] [Full Text] [Related]

  • 40. Functional in vivo MHC class II loading by endogenously synthesized glycoprotein during viral infection.
    Oxenius A, Bachmann MF, Mathis D, Benoist C, Zinkernagel RM, Hengartner H.
    J Immunol; 1997 Jun 15; 158(12):5717-26. PubMed ID: 9190921
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.